Recombinant humanized anti-VEGF monoclonal antibody (Henlius Biotech/Essex Bio-Tech)

重组抗VEGF人源化单克隆抗体（复宏汉霖生物/亿胜生物）

Report date: 2025/10/10 15:03:34

Base Information

Drug NameRecombinant humanized anti-VEGF monoclonal antibody (Henlius Biotech/Essex Bio-Tech)
Drug Alias Name重组抗VEGF人源化单克隆抗体眼用注射液（复宏汉霖生物）recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection重组抗VEGF人源化单克隆抗体眼用注射液贝伐珠单抗HLX04-OHLX04-O +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsWet age-related macular degenerationMacular DegenerationDiabetic Retinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[15] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Henlius Biologics Co LtdShanghai Henlius Biotech IncShanghai Henlius Biopharmaceuticals Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsWet age-related macular degenerationMacular DegenerationDiabetic Retinopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A